The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Real-world use of nivolumab in gastric cancer
Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, discusses the findings of a prospective investigation evaluating clinical outcomes from real-world data of nivolumab treatment in advanced gastric cancer. The real-world data of nivolumab treatment in advanced gastric cancer indicated comparable survival to previous clinical trial data. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Yu Sunakawa, MD, PhD has received grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharma, MSD, Daiichi Sankyo; and grants from Otsuka.
